Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still more evidence that Peregrine is pushing as hard as it can to make a place for itself in the biopharm world.
Paul
Cotara looks like a good product that is getting close to approval, but let's not forget that Bavi is the elephant in the room. As goes Bavi, so goes Peregrine. Let's keep our eyes on the current trials; we should see some results before the end of the year. These trials will move the meter - one way or the other.
Paul
To me this hiring shows confidence that Peregrine is not circling the drain as some seem to think. It looks more like it is taxiing down the runway getting aligned for take off.
I guess the two penny move has gone straight to my head.
Paul
If the MOS data was considered important for good or ill, isn't Peregrine required by the SEC to report it within a certain period?
Paul
I reviewed the new slides from Dr. Thorpe. It seems that he has devoted years of effort to learn why anti-PS therapy, read Bavi, has therapeutic effects. Not a scientist, but it looked impressive to me.
I'm an optimist, but I was not expecting any revelations that would move the SP. Only big news from the clinical trials can move the SP to where we want to go IMO.
Paul
Thanks for keeping us uptodate on Affitech. They are clearly moving forward on our "better Avastin".
Paul
Thanks, CJG. Clinicians apparently think Bavi can make a difference for their patients. I have to think they have a better idea of Bavi's potential than we do.
By the way these trials must cost a lot of money. Management must believe it is close to reaching the partnering/selling stage.
Paul
I guess we see the world through different prisms. By this time next year we will know who saw more clearly.
Paul
It could be a massive bluff, but many on this board have roundly criticized management for failing to promote the company and its prospects effectively. Hard to see how they could go from low key to slick opportunists so quickly.
Paul
I read here a lot criticism of Peregine's management and it BOD. I grant some of it is warranted. However, the one characteristic that strikes me about them is their very high level of confidence.
They don't show any doubt that Peregrine is going to succeed on multiple fronts.
Avid just keeps hiring as though they really expect it to enjoy serious growth.
Cotara is being pushed toward the finish line as though they really expect a lucrative partnering deal.
Bavi is being pushed into every clinical trial possible as though they expect strong results.
If these three efforts succeed, I feel confident that my heroic gamble on this company will work out in a good way.
Paul
It took Fidelity 7 minutes to fill my order of 2000 shares at 2.10. Seems kind of slow to me.
Paul
Thanks for the good luck wish. Avid is hiring, trials are progressing, Peregrine is staying a few steps ahead of the bill collectors, therefore we are have yet another golden opportunity to average down. Let it be the last time!
Paul
I hate it when the PPHM sp tanks for no known reason. I hate it because I have to buy more. In my thinking the risk - the reduced price - declines, while the reward stays the same. Eek.
Paul
It seems that these PPHM dips are rarely associated with bad news.
I am raising a little cash by selling a bond fund that is unlikely to go anywhere. If we start back up, I'll be ready to add.
Paul
Does anybody here follow Affitech? I'm concerned that they won't have the resources to bring the anti-angiogenesis drug we "sold" them through clinical trials.
Paul
Well said Geo. It has been a long wait, but the clinical news from Cotara and Bavi has continued to support the inordinate amount of money some of us have put in PPHM. I hope that before the end of the year we will be feeling even better about our wager on Peregrine.
Paul
I sent an email to Peregrine asking why Avid has recently posted new job openings. I requested that a news release go out to explain what's changed.
Paul
Looks like Avid has a lot of work to do. I'd like to think this means some real revenue growth is coming.
Paul
My brother died last year from GBM. It's sad that Cotara was not available to extend his life. Sometimes it is useful to look at a company like Peregrine from a point of view beyond personal greed.
Paul
The number of months survived is still not what I would want as a prognosis. Adding Bavi to this mix might add still more months. Due to Bavi's unique method of action, it is not a competitor to other drugs, it is a partner that will make them look better.
Paul
You have to wonder who would bet against Peregrine's potential. I have to believe they just don't know much about Peregrine. I believe those of us who have followed it for years are very excited about what may come out over the next few months - something wonderful for anyone who has the foresight to buy at these levels. We'll soon see.
Paul
Somebody seems think Dr. Thorpe is an important guy with a compelling story - Bavi.
http://www.informaglobalevents.com/event/antibodies1
Very reassuring.
Paul
The use of anti-PS - Bavi - as part of a vaccine is something I associated with treating viruses. Very cool to use it on cancers.
Methinks Peregrine may be undervalued by the 99.99% of the market that doesn't really know what Peregrine has stumbled on to.
Paul
Currently enrolling Bavi trials are expected to treat over 400 patients - 345 anticancer + 66 Hepc. For their sakes as well as ours, let's hope for some great outcomes.
Maybe the Rodney Dangerfield of Mab-land will finally get some respect.
Paul
I agree with everything you said. I have about 13k shares; so, compared to me, you are a big guy.
We will soon know if we have a winner or not. I like how the tea leaves look, but until the share price starts moving up I have to be nervous about our little darling.
Paul
Actually, I believe the big purchase was 3,000 shares. My post was meant to be humorous for those who remembered your post from last week.
Paul
I believe it is a plot by one of our posters who told us last week he was planning a big purchase this week. Maybe we should ride on his coattails and buy more shares ourselves.
Paul
The trials are the answer for everything. They are the only reason Peregrine has any chance of succeeding. Everthing else is peripheral. If they succeed, Peregrine will be bought. If they fail, it won't matter who did what to whom when or who could have done what better.
Paul
If the trials pan out, we will have no trouble finding financing or even a buyout at an attractive price.
Paul
Time to ride the seesaw back up to 2.50. No reason to go down, no reason to go up. Until news. Then, we'll see which way we're going.
The trials are running. Kind of like the little ball in the roulette wheel. I don't think there is any middle ground here. Peregrine will flame out or light up our greedy little lives.
Paul
Damn the torpedoes, full speed ahead!
Paul
Thanks, I couldn't find that one. Paul
I think you are correct that the cut Peregrine will have to pay UTSW has not been disclosed. That said, I have no reason to believe that Peregrine would be bet the future of the company on a product they know they'd have to pay a huge royalty fee on - just not likely, is it?
If the trials succeed, we will be more than happy to share a few bucks with the good people at UTSW who made the whole thing possible.
Paul
Can anyone here detect if we have single, largish buyer? Or is it just the usual milling about by the herd?
Paul
We have how many Phase II human trials in process? The market apparently only knows how risky Peregrine is; it doesn't seem to know how promising it is. I guess that's our secret.
If we're right, let's make them pay when our time comes.
Paul
Tony Blair is a great speaker. If he was our president, instead of Mr. King, the whole world would know PPHM. Of course, if the clincal trials don't bear fruit, it wouldn't matter.
So, let's keep our eyes on the prize. NSCLC trials succeed or Cotara blows out the SOC, and maybe we can hire Blair as our compensated spokesperson.
Paul
It seems like we are due for some good news. Does anyone have a crystal ball that shows anything promising on the Peregrine channel?
Bored on an Easter afternoon,
Paul
With Cotara coming within sight of the finish line, perhaps we are ending this long nightmare of depressed shareholder returns. I sure hope so.
Paul
I just love all these clinical trials in progress- lung, breast, pancreatic, prostate, and brain cancers and HepC, Oh My!
Just imagine if they all click. We might not have to worry about the BOD. The competition to gobble up little Peregrine might just take care of all the nagging little issues that have been posted and re-posted here over the 10 years I've been here.
Oh, wouldn't that be sweet.
Paul
Presumably down for routine maintenance. However, it probably wouldn't happen if we had a top notch BOD and the company didn't keep hiring new people.
Paul